Brief: Quanterix Granted Breakthrough Device Designation From US FDA For Blood-Based p-Tau 217 Test For Alzheimer’s Disease
04/03/2024 14:29
March 4 (Reuters) - Quanterix Corp QTRX.O :
* QUANTERIX GRANTED BREAKTHROUGH DEVICE DESIGNATION FROM
U.S. FDA
FOR BLOOD-BASED P-TAU 217 TEST FOR ALZHEIMER’S DISEASE
Source text for Eikon: ID:nBw5WqJ2wa
Further company coverage: QTRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Quanterix
See all newsBrief: Alzpath And Quanterix Expand Strategic Licensing Agreement To Advance Next Generation Alzheimer's Disease Biomarker Research
Quanterix Corporation reports results for the quarter ended June 30 - Earnings Summary
Quanterix Q2 revenue rises 34% but cuts 2026 outlook
Quanterix Corporation expected to post a loss of 46 cents a share - Earnings Preview
Quanterix Corp expected to post a loss of 46 cents a share - Earnings Preview